Search results for "General Veterinary"

showing 10 items of 334 documents

Soluble-protein and antigenic heterogeneity in axenic Blastocystis hominis isolates: pathogenic implications.

1999

The protein profile and the antigenic cross-reactivity of 18 axenic isolates of Blastocystis hominis obtained from symptomatic patients with chronic diarrhea (14 isolates) showing no evidence of parasitic etiology and from patients with acute diarrhea attributable in 2 cases to Salmonella spp. were analyzed. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of soluble proteins showed the existence of a common profile composed of 31 bands, with molecular weights ranging between 24 and >200 kDa, and minor differences in the proteins of 149, 118, 106, 50, 48, 47, and 30 kDa. These differences allowed us to classify the strains into three related patterns (I–III). In an indirect immunof…

AdultDiarrheaSalmonellaImmunodiffusionProtozoan ProteinsAntigens ProtozoanHIV InfectionsBlastocystis InfectionsBiologyLoboseaCross Reactionsmedicine.disease_causeMicrobiologyAntigenmedicineAnimalsHumansBlastocystis hominisAxenicGel electrophoresisBlastocystisGeneral VeterinaryGeneral Medicinebiology.organism_classificationVirologyMolecular WeightDiarrheaInfectious DiseasesInsect ScienceAcute DiseaseChronic DiseaseSalmonella InfectionsProtozoaParasitologyElectrophoresis Polyacrylamide Gelmedicine.symptomParasitology research
researchProduct

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-lab…

2021

Abstract: Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16 & ndash;26 years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27 & ndash;45 versus 16 & ndash;26 years of age. Methods: This international, open-label study (NCT03158220) was conducted in women 16 & ndash;45 years of age. Participants (16 & ndash;26 years, n = 570 and 27 & ndash;45 years, n = 642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 w…

AdultHuman papillomavirusmedicine.medical_specialtyAdolescentAntibodies ViralYoung Adult03 medical and health sciencesNine-valent human papillomavirus vaccineImmunogenicity Vaccine0302 clinical medicine030225 pediatricsInternal medicinemedicineHumansPapillomavirus Vaccines030212 general & internal medicineSeroconversionHPV prophylaxisAdverse effectAgedCervical cancerHuman papillomavirus 16Human papillomavirus 18General VeterinaryGeneral Immunology and Microbiologybusiness.industryPapillomavirus InfectionsAdult vaccinationPublic Health Environmental and Occupational Healthmedicine.diseaseVaccine efficacyConfidence interval3. Good healthVaccinationClinical trialPrecancerRegimenInfectious DiseasesCervical cancerMolecular MedicineFemaleHuman medicinebusinessVaccine
researchProduct

Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults

2000

Abstract To assess the reactogenicity and immunogenicity of the Biken acellular pertussis vaccine (Pa) following administration of a single vaccine dose to young adults with or without a history of prior pertussis immunization, 104 healthy, male and female adults without primary pertussis immunization were enrolled in Mainz (former West Germany; “not previously pertussis vaccinated”, N-PPV-group); in parallel, 103 adults with a history of having received ≥four doses of a combined diphtheria-, tetanus-toxoid, whole-cell pertussis vaccine (DTwP) were enrolled in Magdeburg (former East Germany; “previously pertussis-vaccinated”, PPV-group). Large areas of redness (>20 mm) were seen in 2.9%/1.0…

AdultMaleDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisVaccines AcellularHumansMedicineVirulence Factors BordetellaYoung adultAdhesins BacterialWhooping coughPertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthToxoidAntibody titerToxoidsmedicine.diseaseAntibodies BacterialHemagglutininsInfectious DiseasesImmunologyMolecular MedicinePertussis vaccineFemaleSafetybusinessmedicine.drugVaccine
researchProduct

Are medical residents a "core group" for for future improvement of influenza vaccination coverage in health-care workers? A study among medical resid…

2011

Abstract Despite international recommendations, vaccination coverage among European healthcare workers, including physicians, is widely recognized as unsatisfactory. In order to plan tailored vaccination campaigns and increase future coverage, we investigated reasons for refusing vaccination and determinants associated with influenza vaccine uptake among young health care workers. A survey was carried out during September and October 2010 on medical residents attending post-graduate Schools of the Medical Faculty at the University of Palermo (Italy). Each participant completed an anonymous web-based questionnaire including items on demographic and occupational characteristics, knowledge, at…

AdultMaleHealth Knowledge Attitudes PracticeInfluenza vaccineAttitude of Health PersonnelInfluenza vaccination acceptance healthcare workers medical residentsSettore MED/42 - Igiene Generale E ApplicataHospitals UniversityProfessional CompetenceEnvironmental healthSurveys and QuestionnairesHealth carePandemicInfluenza HumanMedical Staff HospitalMedicineHumansSicilyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational Healthvirus diseasesUniversity hospitalDrug UtilizationVaccinationInfectious DiseasesVaccination CampaignsInfluenza VaccinesVaccination coverageImmunologyHuman mortality from H5N1Molecular MedicineFemalebusiness
researchProduct

Visualizing knowledge and attitude factors related to influenza vaccination of physicians

2014

To characterize groups of primary healthcare physicians according to sociodemographic data, years of professional experience and knowledge of and attitudes to influenza, and to evaluate differences between groups with respect to influenza vaccination in the 2011-2012 season.We carried out an anonymous web survey of Spanish primary healthcare physicians in 2012. Information on vaccination, and knowledge of and attitudes to influenza was collected. Multiple correspondence analysis and cluster analysis were used to define groups of physicians.We included 835 physicians and identified three types. Type B were physicians with low professional experience of influenza. Types A and C were physician…

AdultMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyAttitude of Health PersonnelPrimary health careSevere diseaseSociodemographic dataDisease clusterMultiple correspondence analysisPhysiciansSurveys and QuestionnairesInfluenza HumanmedicineHumansGeneral VeterinaryGeneral Immunology and MicrobiologyTransmission (medicine)business.industryData CollectionVaccinationPublic Health Environmental and Occupational Healthvirus diseasesMiddle AgedVaccinationInfectious DiseasesFamily medicineMolecular MedicineFemalebusinessWeb surveyVaccine
researchProduct

Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy)

2011

The aim of the study was to investigate factors involved in vaccination acceptance among healthcare workers (HCWs) and adverse reactions rates associated with pandemic influenza vaccination. The study was carried out in the major teaching hospital of Sicily from November 2009 to February 2010 on 2267 HCWs. A total of 407 (18%) HCWs were vaccinated against the 2009 pandemic influenza A (H1N1). A logistic regression analysis indicates an increased risk of non-vaccination against pandemic influenza in females (OR = 1.6; 95% CI = 1.3-2.1) compared to males, in nurses/technicians/administrative workers (OR = 1.7; 95% CI = 1.3-2.2) compared to doctors/biologists, and in HCWs who were non-vaccinat…

AdultMalePandemic influenza vaccination healthcare workers adverse reactionsHealth PersonneleducationOrthomyxoviridaeSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeTeaching hospitalSurveys and QuestionnairesEnvironmental healthInfluenza HumanHealth careInfluenza A virusmedicineHumansHospitals TeachingAdverse effectSicilyGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthPandemic influenzavirus diseasesMiddle Agedbiology.organism_classificationVaccinationLogistic ModelsInfectious DiseasesInfluenza VaccinesMultivariate AnalysisImmunologyMolecular MedicineFemaleViral diseasebusinessVaccine
researchProduct

Microvascular Characteristics of the Human Interdental Papilla

2007

The aim of this study was to observe the microcirculation characteristics of the human interdental papilla in healthy patients in vivo. Twenty healthy patients were examined. Capillaroscopy was used to investigate the characteristics of microcirculation of the human periodontal mucosa. Visibility, course, tortuosity, as well as the average caliber of the capillary loops and the number of visible capillary loops per square millimeter were evaluated for each patient. The investigation of gingival mucosa revealed capillary loops with a course both parallel and perpendicular to the surface. Our study has pointed out that capillaroscopy is a reliable method to study periodontal microcirculation …

AdultMalePathologymedicine.medical_specialtyMicroscopy VideoFuture studiesGeneral Veterinarybusiness.industryMicrocirculationGingivaGeneral MedicineMiddle AgedMicrocirculationmedicine.anatomical_structureReference ValuesPeripheral microcirculationmicrovascular interdental papillaReference valuesGingival mucosaHumansMedicineFemalebusinessInterdental papillaPeriodontal DiseasesAnatomia, Histologia, Embryologia: Journal of Veterinary Medicine Series C
researchProduct

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

2011

Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes for preventing invasive pneumococcal disease. Objective: The objective of this study was to estimate the potential health benefits, costs, and cost-effectiveness of vaccination with PCV-13 in the Community of Valencia and to generate valuable information for policy makers at regional and country levels. Methods: A decision tree was designed to determine the health and economic outcomes in hypothetical cohorts of vaccinated and unvaccinate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCost effectivenessPharmacoeconomic assessmentCost-Benefit AnalysisPneumococcal conjugate vaccinePneumococcal InfectionsHerd immunityPneumococcal VaccinesIndirect costsYoung AdultEnvironmental healthmedicineHeptavalent Pneumococcal Conjugate VaccineHumansChildAgedAged 80 and overGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfant NewbornInfantMiddle AgedQuality-adjusted life yearVaccinationInfectious DiseasesSpainChild PreschoolCohortMolecular MedicineCost-effectivenessFemalebusinessmedicine.drugVaccine
researchProduct

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccinatio…

2009

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adu…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross Protectionmedicine.medical_treatmentPopulationImmunization SecondaryBooster doseAntibodies ViralYoung AdultAdjuvants ImmunologicImmunityInfluenza Humanparasitic diseasesmedicineHumansAS03educationeducation.field_of_studyBooster (rocketry)Influenza A Virus H5N1 SubtypeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthHemagglutination Inhibition TestsMiddle AgedImmunity HumoralVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Effectiveness of pandemic and seasonal influenza vaccines in preventing pandemic influenza-associated hospitalization.

2011

Vaccines are leading pharmacological measures for limiting the impact of pandemic influenza in the community. The objective of this study was to investigate the effectiveness of influenza (pandemic and seasonal) vaccines in preventing pandemic influenza-associated hospitalization. We conducted a multicenter matched case-control study in 36 Spanish hospitals. Patients hospitalized with confirmed pandemic influenza between November 2009 and February 2010 and two hospitalized controls per case, matched according to age, date of hospitalization and province of residence, were selected. Multivariate analysis was performed using conditional logistic regression. Subjects were considered vaccinated…

AdultMalePediatricsmedicine.medical_specialtyMultivariate analysisAdolescentSeasonal influenzaYoung AdultPandemicInfluenza HumanMedicineHumansYoung adultChildAgedAged 80 and overGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthPandemic influenzaCase-control studyInfant Newbornvirus diseasesInfantMiddle AgedHospitalsVaccinationHospitalizationInfectious DiseasesInfluenza VaccinesSpainCase-Control StudiesChild PreschoolImmunologyHuman mortality from H5N1Molecular MedicineFemalebusinessVaccine
researchProduct